Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression

BACKGROUND: Atezolizumab may provide clinical benefits to patients with advanced non-small cell lung cancer (NSCLC). However, the price of atezolizumab is relatively high, and its economic outcomes have remained unclear. In this study, we used two models to examine the cost-effectiveness of initial...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chuan, Liu, Yue, Tan, Jing, Tian, Panwen, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043365/
https://www.ncbi.nlm.nih.gov/pubmed/36998459
http://dx.doi.org/10.3389/fonc.2023.1093469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043365/
https://www.ncbi.nlm.nih.gov/pubmed/36998459
http://dx.doi.org/10.3389/fonc.2023.1093469

Ejemplares similares